Advertisement

Reversal of multidrug resistance by B859-35, a metabolite of B859-35, niguldipine, verapamil and nitrendipine

  • J. Hofmann
  • A. Wolf
  • M. Spitaler
  • G. Böck
  • J. Drach
  • Christof Ludescher
  • Hans Grunicke
Original Papers Experimental Oncology

Summary

It has been shown previously that verapamil and other calcium antagonists and calmodulin inhibitors can reverse multidrug resistance. We compared the potency of the dihydropyridine derivatives (4R)-3-[3-(4,4-diphenyl-l-piperadinyl)-propyl]-5-methyl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-pyridine-3,5-dicarboxylate-hydrochloride (B859-35), a metabolite of B859-35, niguldipine and (R)-nitrendipine to that of (RS)-verapamil in reversing multidrug resistance. The accumulation of the fluorescent dye rhodamine 123, which is transported by the P-glycoprotein, was determined by a flow cytometer. Multidrug-resistant human HeLa KB-8-5 and Walker rat carcinoma cells were incubated in the presence and in absence of the drugs indicated above. We found that 0.1 μM B859-35 increases the accumulation of rhodamine 123 in multidrug-resistant KB-8-5 and Walker cells more effectively than 1 μM (RS)-verapamil. In sensitive KB-3-1 cells addition of the drugs had no significant influence on the accumulation of rhodamine 123. In KB-8-5 cells, 10 nM Adriamycin caused a reduction of cell growth to 85% compared to untreated controls (=100%). If 1 μM B859-35, B859-35 metabolite, niguldipine, verapamil or (R)-nitrendipine was added to 10 nM Adriamycin, growth reduction compared with untreated controls increased to 12%, 11%, 23%, 63%, and 82% respectively. The effect of 0.1 μM B859-35 was a reduction in proliferation to 38%, that of 0.1 μM verapamil to 72%. These data illustrate that B859-35, a compound with antitumor activity in several tumors, is at least ten times more potent than racemic verapamil in reversing multidrug resistance.

Key words

Verapamil B859-35 Multidrug resistance P-170-glycoprotein Adriamycin 

Abbreviations

B859-35

(4R)-3-[3-(4,4-diphenyl-1-piperidinyl)-propyl]-5-methyl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-pyridine-3,5-dicarboxylatehydrochloride

B859-35

metabolite, (4R)-3-[3,(4,4-diphenyl-1-piperidinyl)-propyl]-5-methyl-2,6-dimethyl-4-(3-nitrophenyl)-pyridime-3,5-dicarboxylatehydrochloride

MOPS

3-N-morpholinopropanesulfonic acid

MDRI

human multidrugresistance gene

WR

Walker cells resistant to alkylating agents and also multidrug-resistant

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abdallah F, Gietzen K (1990) Inhibition of cell proliferation by dihydropyridine derivatives. Naunyn Schmiedeberg's Arch Pharmacol 341:R45Google Scholar
  2. Akiyama S, Fojo A, Hanover JA, Pastan I, Gottesmann MM (1985) Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somatic Cell Mol Genet 11:117–126Google Scholar
  3. Benson III AB, Trump DL, Koeller JM, Egorin MI, Olman EA, Witte RS, Davis TE, Formey DC (1985) Phase I study of vinblastin and verapamil given by concurrent iv infusion. Cancer Treat Rep 69:795–799Google Scholar
  4. Bliek A van der, Borst P (1989) Multidrug resistance. Adv Cancer Res 52:165–203Google Scholar
  5. Broxterman HJ, Kuiper CM, Schuurhuis GJ, Hoeven JJM van der, Pinedo HM, Lankelma J (1987) Daunomycin accumulation in resistant tumor cells as a screening model for resistance modifying drugs: role of protein binding. Cancer Lett 35:87–95Google Scholar
  6. Chatterjee M, Harris AL (1990) Enhancement of Adriamycin cytotoxicity in a multidrug resistant Chinese hamster ovary (CHO) subline, CHO-Adrr, by toremifene and its modulation by alpha acid glycoprotein. Eur J Cancer 26:432–436Google Scholar
  7. Bucana CD, Giavazzi R, Nayar R, O'Brian C, Seid CC, Earnest L, Fan D (1990) Retention of vital dyes correlates inversely with the multidrug-resistant phenotype of Adriamycin-selected murine fibrosarcoma variants. Exp Cell Res 190:69–75Google Scholar
  8. Efferth T, Löhrke H, Volm M (1989) Reciprodal correlation between expression of P-glycoprotein and accumulation of rhodamine 123 in human tumors. Anticancer Res 9:1633–1638Google Scholar
  9. Eltze M, Boer R, Sanders KH, Boss H, Ulrich W-R, Flockerzi D (1990) Stereoselective inhibition of thromboxane-induced coronary vasoconstriction by 1,4-dihydropyridine calcium channel antagonists. Chirality 2:233–240Google Scholar
  10. Finlay GG, Baguley BC, Snow K, Judd W (1990) Multiple patterns of human leukemia cell sublines to amsacrina analogues. J. Natl Cancer Inst 82:662–668Google Scholar
  11. Gietzen K, Abdallah F, Bai G (1990) Selective inhibition of proliferation by a novel dihydropyridine derivative with anti-calmodulin activity in the mamma tumor cell line ZR-75-1. Med Sci Res 18:627–629Google Scholar
  12. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai S, Gadzdar A, Pirker R, Green A, Crist W, Garrett BM, Lieber M, Cossman J, Gottesman MM, Pastan I (1989) Experession of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81:116–124Google Scholar
  13. Gottesman MM (1988) Multidrug resistance during chemical carcinogenesis: a mechanism revealed? J Natl Cancer Inst 80:1352–1353Google Scholar
  14. Häussermann K, Benz B, Roller E, Gekeler V, Schuhmacher K, Eichelbaum M (1990) Cytotoxic effects of the new Ca++/calmodulin antagonist B859-35 on sensitive and MDR cell lines. J Cancer Res Clin Oncol 116:A4.114.30Google Scholar
  15. Herweijer H, Sonneveld P, Baas F, Nooter K (1990) Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine. J Natl Cancer Inst 82:1133–1140Google Scholar
  16. Hofmann J, Ueberall F, Egle A, Grunicke H (1991) B-859-35, a new drug with antitumor activity reverses multidrug resistance. Int J. Cancer 47:870–875Google Scholar
  17. Huebel U, Hamann JH, Reznik GK (1990) Successful therapy of dimethylbenzanthrazene (DMBA) induce mammary gland carcinomas in rats with a new antagonist of Ca++/calmodulin. J Cancer Res Clin Oncol 116:446Google Scholar
  18. Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152–162, 1976Google Scholar
  19. Kartner N, Evernden-Porelle D, Bradley G, Ling V (1985) Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 316:820–823Google Scholar
  20. Neyfakh AA (1988) Use of fluorescent dyes as molecular probes for the study of multidrug resistance. Exp Cell Res 174:168–176Google Scholar
  21. Noonan KE, Beck C, Holzmayer TA, Chin JE, Wunder JS, Andrulis IL, Gazdar AF, Willman CL, Griffith B, Hoff DD von, Roninson IB (1990) Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 87:7160–7164Google Scholar
  22. Pirker R, Keilhauer GK, Raschak M, Lechner C, Ludwig H (1990) Reversal of multi-drug resistance in human KB cell lines by structural analogs of verapamil. Int J Cancer 45:916–919Google Scholar
  23. Schuller HM, Correa E, Orloff M, Reznik GK (1990) Successful chemotherapy of experimental neuroendocrine lung tumors in hamsters with an antagonist of Ca++/calmodulin. Cancer Res 50:1645–1649Google Scholar
  24. Shen DW, Cararelli C, Hwang J, Cornwell M, Reichert N, Ishiii S, Pastan I, Gottesman MM (1986) Multiple drug resistant human KB carcinoma cell independently selected for high level resistance to colchicine, Adriamycin, or vinblastine show changes in expression of specific proteins. J Biol Chem 261:7762–7770Google Scholar
  25. Smith PJ (1990) DNA topoisomerase dysfunction: a new goal for antitumor chemotherapy. Bioessays 12:167–172Google Scholar
  26. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967–1972Google Scholar
  27. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1982) Increased accumulation of vincristine and Adriamycin in drug-resistant P388 tumor cell following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 42:4730–4733Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • J. Hofmann
    • 1
  • A. Wolf
    • 1
  • M. Spitaler
    • 1
  • G. Böck
    • 2
  • J. Drach
    • 3
  • Christof Ludescher
    • 3
  • Hans Grunicke
    • 1
  1. 1.Institute of Medicinal Chemistry and BiochemistryUniversity of InnsbruckInnsbruckAustria
  2. 2.Institute of General and Experimental PathologyUniversity of InnsbruckInnsbruckAustria
  3. 3.Department of Internal MedicineUniversity of InnsbruckInnsbruckAustria

Personalised recommendations